| Gene symbol | MAGEA3 | Synonyms | CT1.3, HIP8, HYPD, MAGE3, MAGEA6 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | MAGE family member A3 | ||||
| Gene symbol | MAGEC1 | Synonyms | CT7, CT7.1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq27.2 | dbXrefs | |
| Description | MAGE family member C1 | ||||
| Gene symbol | WT1 | Synonyms | AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1, WT33 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | WT1 transcription factor | ||||
| GTO ID | GTC0191 |
| Trial ID | NCT01995708 |
| Disease | Myeloma |
| Altered gene | MAGE-C1|MAGE-A3|WT1 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | LC Vaccine |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation |
| Year | 2014 |
| Country | United States |
| Company sponsor | Memorial Sloan Kettering Cancer Center |
| Other ID(s) | 13-009 |
| Vector information | |||
|
|||
| Cohort1: LC vaccines | |||||||||||||||
|
|||||||||||||||
| Cohort2: Standard of care | |||||||||||||||
|
|||||||||||||||